Palatin Technologies

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Palatin Technologies reports revenue challenges but advances pipeline programs

Palatin Technologies faced revenue challenges in Q3 2024 but showcased strengths in pipeline advancements and positive clinical results.
The company's financial performance improved despite increased operating expenses, with a focus on expanding clinical programs and enhancing drug profiles.
While facing cash utilization concerns and upcoming study expenses, Palatin remains optimistic about its progress and future milestones.

Palatin Technologies reports Q4 loss, progresses in ocular treatments

Palatin Technologies navigated Q4 2024 with a focus on cost reduction and asset sales, impacting revenue and expenses.
Despite financial challenges, the company's progress in ocular programs and pipeline development showcases strategic advancements.
Opportunities lie in leveraging asset sale proceeds, advancing clinical programs, and addressing funding needs for future growth.

Palatin Technologies focuses on obesity programs amid financial challenges

Palatin Technologies navigated challenges in Q1 2024 with no product sales and a net loss, while managing operating expenses effectively.
The company's focus on core obesity programs and upcoming study results indicate strategic alignment and progress in key initiatives.
Despite financial constraints and timing risks, Palatin's exploration of strategic options and pipeline advancement offer growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRANBURY, N.J., March 5, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced that Carl...

Palatin Technologies to Participate in H.C. Wainwright Global Life Sciences Virtual Conference

Palatin Technologies' (PTN) CEO Carl Spana on Q2 2021 Results - Earnings Call Transcript

Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of -100.00% and -182.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Palatin Technologies, Inc. (PTN) Reports Q2 Loss, Lags Revenue Estimates

CRANBURY, N.J., Feb. 17, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today...

Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2021 Financial Results and Recent Business Highlights

CRANBURY, N.J., Feb. 12, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2021 operating results on Wednesday, February 17, 2021 before the open of the U.S. financial markets. Palatin will also conduct a conference call and...

Palatin Technologies, Inc. to Report Second Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on February 17, 2021

Palatin (PTN) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Palatin (PTN) Jumps: Stock Rises 8.7%

Palatin Technologies Inc (NYSE: PTN) filed an international patent application under the Patent Cooperation Treaty (PCT) related to the composition of PL9643 and a related family of melanocortin agonist peptides. The application establishes the base for the presumptive patent term, and if a patent is granted, it could provide patent protection out to 2041.

Palatin Shares Spikes On International Patent Application Covering Its Dry Eye Disease Candidate

CRANBURY, N.J., Feb. 10, 2021 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced the filing...

Palatin Technologies Announces Filing of International Patent Application Claiming PL9643

Vyleesi sales are likely to be in focus when Palatin (PTN) releases results for the second quarter of fiscal 2021.

Palatin (PTN) to Report Q2 Earnings: What's in the Cards?

Is (PTN) Outperforming Other Medical Stocks This Year?

Has Palatin Technologies (PTN) Outpaced Other Medical Stocks This Year?

CRANBURY, N.J., Dec. 15, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced positive...

Palatin Technologies Announces Positive Results From its Phase 2 Study of PL9643 in Patients With Dry Eye Disease

Palatin Technologies (PTN) saw a big move last session, as its shares jumped 8% on the day, amid huge volumes.

Palatin Technologies (PTN) Surges: Stock Moves 8% Higher

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q1 2021 Results - Earnings Call Transcript

CRANBURY, N.J., Nov. 17, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today...

Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2021 Results and Provides Business Update

CRANBURY, N.J., Nov. 12, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2021 operating results on Tuesday, November 17, 2020 before the open of the U.S. financial markets. Palatin will also conduct a conference call and...

Palatin Technologies, Inc. to Report First Quarter, Fiscal Year 2021 Results; Teleconference and Webcast to be held on November 17, 2020

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q4 2020 Results - Earnings Call Transcript

CRANBURY, N.J., Sept. 28, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today...

Palatin Technologies, Inc. Announces Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Business Update

CRANBURY, N.J., Sept. 24, 2020 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2020 operating results on Monday, September 28, 2020 before the open of the U.S. financial markets. Palatin will also conduct a conference...

Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2020 Results; Teleconference and Webcast to be held on September 28, 2020

CRANBURY, N.J., Sept. 10, 2020 /PRNewswire/ -- Palatin Technologies, Inc.

Palatin Technologies To Present At The H.C. Wainwright & Co.

CRANBURY, N.J., Aug. 13, 2020 /PRNewswire/ -- Palatin Technologies, Inc.

Palatin Technologies Participates In Canaccord Genuity's 40th Annual Growth Conference

CRANBURY, N.J., Aug. 5, 2020 /PRNewswire/ -- Palatin Technologies, Inc.

Palatin Technologies, Inc. Announces Completion of Enrollment of Phase 2 Study with PL9643 for the Treatment of Dry Eye Disease

Shares of Palatin Technologies Inc. PTN, +2.50% gained 31.8% in premarket trading on Tuesday after it said it would test one of its investigational drugs as a treatment for COVID-19.

Palatin's stock rises on plans to test experimental drug as COVID-19 treatment

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q3 2020 Results - Earnings Call Transcript

Palatin Technologies, Inc. (PTN) CEO Carl Spana on Q2 2020 - Earnings Call Transcript

Palatin Technologies' (PTN) CEO Carl Spana on Q1 2020 Results - Earnings Call Transcript

News for Palatin Technologies Stock (PTN)